Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Bright Minds Biosciences Inc (DRUG)

91 + Investors. Track Smart Money conviction in DRUG. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +18
Streak
7Q ▲
Buyers last Q
74%

Smart Money Signals — DRUG

Based on 91 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 7 quarters in a row

last 6Q
For 7 consecutive quarters, more hedge funds added DRUG than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
🏔️

At the ownership peak (100% of max)

100% of all-time peak
91 hedge funds hold DRUG right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
🚀

Fast accumulation — +168% more funds vs a year ago

fund count last 6Q
+57 new funds entered over the past year (+168% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.
🟢

More buyers than sellers — 74% buying

71 buying25 selling
Last quarter: 71 funds were net buyers (28 opened a brand new position + 43 added to an existing one). Only 25 were sellers (15 trimmed + 10 sold completely). A clear majority buying is a strong confirmation signal.
📈

More new buyers each quarter (+9 vs last Q)

new funds entering per quarter
Funds opening a new DRUG position: 23 → 15 → 19 → 28. A growing influx of new institutional buyers means the asset is still gathering momentum — the consensus hasn't fully saturated yet.
🔄

Mostly new holders — 53% entered in last year

■ 3% conviction (2yr+) ■ 44% medium ■ 53% new
Only 3 funds (3%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.
📈

Growing discovery — still being found

10 → 23 → 15 → 19 → 28 new funds/Q
New funds entering each quarter: 23 → 15 → 19 → 28. A growing number of institutions are discovering DRUG each quarter. The narrative is still spreading — leaving room for ongoing capital accumulation.
🌱

Early stage — 71% of holders entered in last year

■ 7% veterans ■ 22% 1-2yr ■ 71% new
Of 91 current holders: 65 (71%) entered in the past year, only 6 (7%) are 2+ year veterans. This is an early-phase institutional idea — still being discovered. High upside potential if the thesis plays out, but thin conviction base.
✅

Strong quality — 23% AUM from major funds

23% from top-100 AUM funds
27 of 91 holders rank in the top 100 by AUM, accounting for 23% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.
5.8
out of 10
Moderate Exit Risk
Exit risk score 5.8/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — DRUG

In 2026 Q1, 71 hedge funds were net buyers of DRUG (28 opened a new position, 43 added to an existing one), while 25 reduced or exited (15 trimmed, 10 sold completely) — a 74% buyer ratio, indicating clear institutional accumulation. This marks 7 consecutive quarters of net institutional buying — a persistent conviction signal. 23% of total institutional value in DRUG is held by top-100 AUM funds, reflecting strong institutional quality. Net fund flow last quarter: +18 funds (more new holders than closures). Total institutional holders: 91.

Hedge Fund Ownership: DRUG

How many hedge funds hold DRUG — quarterly history vs. share price
Quarterly hedge fund ownership of DRUG vs. share price

Market Analysis: DRUG

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: DRUG

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Bright Minds Biosciences Inc (DRUG) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much DRUG has moved relative to its sector benchmark (XLV) since the 2026 Q1 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End March 31, 2026 · 80d ago
DRUG
nan%
XLV
+2.1%

DRUG outperformed XLV by nan% since March 31, 2026.

Since 13F Filing Date May 15, 2026 · 35d ago
DRUG
nan%
XLV
+3.2%

Since the filing became public, DRUG outperformed XLV by nan% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

10 top-rated funds 3 high-conviction
Consensus
4.5
/ 10
breadth
×
Elite
3.3
/ 10
conviction
Hedge Fund Positioning: DRUG
91 + Investors

Track Smart Money conviction in DRUG. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 91 73 24.66%
13F Shares 9M 7M 39.32%
Total Value $669M $515M 30.02%
New Positions 28 19 +9
Increased Positions 43 25 +18
Closed Positions 10 6 +4
Reduced Positions 15 19 -4
Total Calls 0 0 -
Total Puts 0 0 -
PUT/CALL Ratio 0.0 0.0 Bullish

Statistics: DRUG

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

91 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in DRUG. Verified SEC 13F-HR filings.

QUARTER:
Top 25 DRUG holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Acuta Capital Partners, LLC 5.76% 111,996 $8.2M
2 Cormorant Asset Management, LP 3.88% 1,059,331 $77.3M
3 Great Point Partners LLC 3.69% 220,000 $16.1M
4 B Group, Inc. 3.65% 67,500 $4.9M
5 Vivo Capital, LLC 3.39% 557,172 $40.7M
6 KVP Capital Advisors, LP 1.73% 31,813 $2.3M
7 Braidwell LP 1.31% 539,708 $39.4M
8 MPM BioImpact LLC 1.20% 212,175 $15.5M
9 Vestal Point Capital, LP 1.00% 492,319 $35.9M
10 Ikarian Capital, LLC 0.99% 166,647 $12.2M
11 Sio Capital Management, LLC 0.90% 86,083 $6.3M
12 Superstring Capital Management LP 0.69% 13,311 $971K
13 Seven Grand Managers, LLC 0.59% 120,000 $8.8M
14 Artia Global Partners LP 0.56% 38,407 $2.8M
15 Perceptive Advisors LLC 0.54% 377,544 $27.5M
16 Platinum Investment Management Ltd 0.35% 19,127 $1.4M
17 Parkman Healthcare Partners LLC 0.30% 40,098 $2.9M
18 Deerfield Management Company, L.P. 0.24% 283,000 $20.7M
19 Driehaus Capital Management LLC 0.23% 432,515 $31.6M
20 Ra Capital Management, L.P. 0.20% 265,000 $19.3M
21 AdvisorShares Investments LLC 0.17% 12,613 $920K
22 Eventide Asset Management, LLC 0.16% 130,013 $9.5M
23 Seven Fleet Capital Management LP 0.15% 6,395 $467K
24 ADAR1 Capital Management, LLC 0.15% 33,900 $2.5M
25 Informed Momentum Co LLC 0.08% 9,189 $671K
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Bright Minds Biosciences Inc (DRUG)

What does the Smart Money Trend signal show for DRUG?

Buying streak — 7 quarters in a row: For 7 consecutive quarters, more hedge funds added DRUG than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for DRUG?

More buyers than sellers — 74% buying: Last quarter: 71 funds were net buyers (28 opened a brand new position + 43 added to an existing one). Only 25 were sellers (15 trimmed + 10 sold completely). A clear majority buying is a strong confirmation signal.

What is the fund quality score for DRUG holders?

Strong quality — 23% AUM from major funds: 27 of 91 holders rank in the top 100 by AUM, accounting for 23% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

How long have hedge funds held DRUG?

Mostly new holders — 53% entered in last year: Only 3 funds (3%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.

Is it too late to buy Bright Minds Biosciences Inc (DRUG) following the 2026 Q1 hedge fund 13F filings?

As of today, DRUG has moved nan% since the 2026 Q1 13F filing date (May 15, 2026), compared to +3.2% for the XLV sector ETF — an outperformance of nan%. Since the quarter end (March 31, 2026), DRUG has gained nan% vs +2.1% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →